Published in Curr Oncol on October 01, 2006
Preformulation, formulation, and in vivo efficacy of topically applied apomine. Int J Pharm (2009) 0.76
Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer (2004) 2.31
COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis (1998) 2.30
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog (1999) 1.95
Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol (2006) 1.85
TNF-alpha and IL-8 are upregulated in the epidermis of normal human skin after UVB exposure: correlation with neutrophil accumulation and E-selectin expression. J Invest Dermatol (1997) 1.19
The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer (2000) 1.00
Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res (2004) 0.97
Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol (2000) 0.85
Photoprotection by sunscreens. Am J Clin Dermatol (2001) 0.85
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 2.90
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Colon cancer reduction. Questions about implementation of proven techniques. Arch Intern Med (1997) 2.12
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst (1994) 2.05
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res (1995) 1.94
Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology (2001) 1.88
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev (2001) 1.87
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs (1996) 1.49
Analogues of amonafide and azonafide with novel ring systems. J Med Chem (2000) 1.47
Effect of beta-carotene on lymphocyte subpopulations in elderly humans: evidence for a dose-response relationship. Am J Clin Nutr (1991) 1.45
Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomarkers Prev (1999) 1.42
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet (1980) 1.30
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Measurement of chemopreventive efficacy in skin biopsies. Anal Quant Cytol Histol (2001) 1.25
Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst (1994) 1.23
High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol (1981) 1.21
Karyometry in the early detection and chemoprevention of intraepithelial lesions. Eur J Cancer (2005) 1.20
Pharmacokinetics of very high-dose oral melphalan in cancer patients. Am J Clin Oncol (1990) 1.20
Cutaneous plasmacytomas in myeloma. Relationship to tumor cell burden. Arch Dermatol (1978) 1.19
The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther (1971) 1.16
Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet (1996) 1.15
Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med (1981) 1.14
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res (1976) 1.13
Nuclear morphometry in solar keratosis. Anal Quant Cytol Histol (1998) 1.12
Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res (1999) 1.12
Hydrolysis and protein binding of melphalan. J Pharm Sci (1978) 1.10
Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett (1994) 1.10
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol (1984) 1.08
Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. Int J Cancer (2001) 1.07
Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. Prog Clin Biol Res (1980) 1.06
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol (1999) 1.05
Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst (1999) 1.05
Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial. Cancer Epidemiol Biomarkers Prev (1997) 1.05
Investigating sun-damaged skin and actinic keratosis with optical coherence tomography: a pilot study. Technol Cancer Res Treat (2003) 1.04
Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev (1994) 1.03
Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev (1997) 1.02
Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (1999) 1.02
Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs (2003) 1.01
Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression. Cancer Lett (2001) 1.01
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.01
Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer (1996) 1.01
Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology (2001) 1.00
The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer (2000) 1.00
A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer (2007) 1.00
High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci (1978) 0.99
Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol (1981) 0.98
Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol (1987) 0.97
Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev (1997) 0.97
Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl (1992) 0.96
Bleomycin pharmacokinetics in man. I. Intravenous administration. Cancer Chemother Pharmacol (1978) 0.96
Bleomycin pharmacokinetics in man. II. Intracavitary administration. Cancer Chemother Pharmacol (1979) 0.96
In vitro drug assay: pharmacologic considerations. Prog Clin Biol Res (1980) 0.96
Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol (1983) 0.96
Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. Br J Cancer (1978) 0.95
New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep (1981) 0.94
Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res (1996) 0.94
Oral melphalan kinetics. Clin Pharmacol Ther (1979) 0.94
Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev (1997) 0.93
Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol (1984) 0.93
Interactions of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Res (1985) 0.93
Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. Cancer Clin Trials (1981) 0.92
Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer (1999) 0.92
Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res (1988) 0.92
Clinical correlations of drug sensitivity in the human tumor stem cell assay. Recent Results Cancer Res (1980) 0.92
Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. Genes Chromosomes Cancer (2000) 0.91
Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia (1999) 0.91
Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep (1982) 0.90
Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet Cytogenet (1997) 0.90
Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res (1987) 0.90
Disposition of mitoxantrone in cancer patients. Cancer Res (1985) 0.90
Comparative pharmacokinetics of chlorambucil and melphalan in man. Recent Results Cancer Res (1980) 0.90
In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol (1982) 0.90
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. J Med Chem (1991) 0.90
Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen. Cancer Treat Rep (1984) 0.89
Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer. Nutr Cancer (2011) 0.89
The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol (1980) 0.89
Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Nutr Cancer (1996) 0.89
Measurement of prostaglandin E2 in rectal mucosa in human subjects: a method study. Cancer Epidemiol Biomarkers Prev (1995) 0.89
Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse. Lancet (1976) 0.88
Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control (2012) 0.88
Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy. Cancer Chemother Pharmacol (1981) 0.88
Clinical correlations of in vitro drug sensitivity. Prog Clin Biol Res (1980) 0.88
Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res (2001) 0.88
Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother Rep (1975) 0.88
In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol (1985) 0.88
Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer (1989) 0.88
Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst (1980) 0.88
Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer (1981) 0.88
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol (2013) 0.87
Comparison of B-mode ultrasonography and computed tomography in gynecologic cancer. Gynecol Oncol (1979) 0.87
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol (1993) 0.87
Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep (1983) 0.85